You are here
Tetraphase Pharmaceuticals to Participate at Upcoming Investor Conferences
WATERTOWN, Mass., Aug. 27, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will participate at the following upcoming investor conferences:
- B. Riley FBR Healthcare Conference and Panel Discussion: “Vaccines and antibiotics can't be developed for intractable infectious diseases” (Track 1: The Great Debates: Controversies in Biotech) on Tuesday, September 4, 2018 at 1:55 p.m. Eastern Time at the New York Marriott East Side Hotel in New York City.
- H. C. Wainwright 20th Annual Global Investment Conference on Wednesday, September 5, 2018 at 12:30 p.m. Eastern Time at the St. Regis Hotel in New York City.
A live audio webcast of the H. C. Wainwright presentation will be available on the company’s website at http://ir.tphase.com/events.cfm. The archived presentation will be available for 30 days.
About Tetraphase Pharmaceuticals, Inc.
Tetraphase is a biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of the multidrug-resistant bacteria highlighted as urgent public health threats by the World Health Organization and Centers for Disease Control and Prevention. The Company has created more than 3,000 novel tetracycline compounds using its proprietary technology platform. Tetraphase's pipeline includes three antibiotic clinical candidates: eravacycline, TP-271 and TP-6076. Eravacycline has completed phase 3 clinical testing and is under review for potential approval in cIAI by the U.S. Food and Drug Administration, with a Prescription Drug User Fee Act date of August 28, 2018 and has received a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency. TP-271 and TP-6076 are in phase 1 clinical trials. Please visit www.tphase.com for more company information.
Media and Investor Contact: